EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Klinische Studie (Phase I)Multizentrische StudieOpen Access

Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma

Naresh Bumma, Joshua Richter iD, Sundar Jagannath iD, Hans C Lee iD, James E Hoffman, Attaya Suvannasankha iD, Jeffrey A Zonder iD, Mansi R Shah iD, Suzanne Lentzsch iD, Rachid Baz iD, Joseph J Maly, Swathi Namburi und 20 weitere

Journal of Clinical Oncology · 2024-08 · 42 (22) · 2702-2712

DOI: 10.1200/jco.24.01008 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Journal of Clinical Oncology, 2024-08. Verfasst von Naresh Bumma und 31 weiteren Autor:innen. Beteiligte Einrichtung: The Ohio State University Comprehensive Cancer Center, Columbus, OH. Hauptthemen laut MEDLINE: Multiple Myeloma, Antibodies, Bispecific. Die Arbeit wurde bisher 209-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE We present a phase I/II first-in-human trial evaluating the safety and efficacy of 50 mg and 200 mg doses of linvoseltamab, a B-cell maturation antigen × CD3 bispecific antibody in relapsed/refractory multiple myeloma (RRMM). METHODS Phase II eligible patients had RRMM that either progressed on/after ≥three lines of therapy including a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-CD38 antibody or was triple-class (PI/IMiD/anti-CD38) refractory. Phase II treatment was once a week through week 14 and then once every 2 weeks. Phase II 200 mg patients who achieved a ≥very good partial response by week 24 received linvoseltamab once every 4 weeks. The primary end point in phase II was overall response rate (ORR). RESULTS Among the 117 patients treated with 200 mg, the median age was 70 years, 39% had high-risk cytogenetics, and 28% had penta-refractory disease. At a median follow-up of 14.3 months, the ORR was 71%, with 50% achieving ≥complete response (CR). In 104 patients treated with 50 mg at a median follow-up of 7.4 months, the ORR was 48%, with 21% achieving ≥CR. The median duration of response (DOR) for 200 mg patients (n = 83) was 29.4 months (95% CI, 19.2 to not evaluable). Among 200 mg patients, the most common adverse events included cytokine release syndrome (35.0% Gr1, 10.3% Gr2, 0.9% Gr3), neutropenia (0.9% Gr2, 18.8% Gr3, 23.1% Gr4), and anemia (3.4% Gr1, 4.3% Gr2, 30.8% Gr3). Immune effector cell-associated neurotoxicity syndrome occurred in 7.7% of patients (2.6% each Gr1, Gr2, Gr3). Infections were reported in 74.4% of patients (33.3% Gr3, 2.6% Gr4); infection frequency and severity declined over time. CONCLUSION Linvoseltamab 200 mg induced deep and durable responses, with a median DOR of 29.4 months, in patients with RRMM with an acceptable safety profile.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaAntibodies, BispecificHumansAgedMaleFemaleMiddle AgedAged, 80 and overB-Cell Maturation AntigenAdultNeoplasm Recurrence, Local

Substanzen

Antibodies, BispecificB-Cell Maturation Antigen

Autor:innen und Institutionen

  • The Ohio State University Comprehensive Cancer Center, Columbus, OH.
  • Icahn School of Medicine at Mount Sinai, New York, NY.
  • The University of Texas MD Anderson Cancer Centre, Houston, TX.
  • University of Miami Health System, Miami, FL.
  • Indiana University Simon Cancer Center and Roudebush VAMC, Indianapolis, IN.
  • Karmanos Cancer Institute, Detroit, MI.

ORCID-Profile: Joshua Richter, Sundar Jagannath, Hans C Lee, Attaya Suvannasankha, Jeffrey A Zonder, Mansi R Shah, Suzanne Lentzsch, Rachid Baz, Matthew J Pianko, Ka Lung Wu, Rebecca Silbermann, Markus Munder, Ja Min Byun, Joaquín Martínez-Lopez, Kaniel Cassady, Glenn S Kroog, Madhav V Dhodapkar

Zitieren

APA

Bumma, N., Richter, J., Jagannath, S., Lee, H. C., Hoffman, J. E., Suvannasankha, A., Zonder, J. A., Shah, M. R., Lentzsch, S., Baz, R., Maly, J. J., Namburi, S., Pianko, M. J., Ye, J. C., Wu, K. L., Silbermann, R., Min, C. K., Vekemans, M. C., Munder, M., …, & Dhodapkar, M. V. (2024). Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma. Journal of Clinical Oncology, 42(22), 2702-2712. https://doi.org/10.1200/jco.24.01008

Vancouver

Bumma N, Richter J, Jagannath S, Lee HC, Hoffman JE, Suvannasankha A, et al. Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma. Journal of Clinical Oncology. 2024;42(22):2702-2712. doi:10.1200/jco.24.01008

BibTeX
@article{Bumma2024,
  author = {Bumma, Naresh and Richter, Joshua and Jagannath, Sundar and Lee, Hans C and Hoffman, James E and Suvannasankha, Attaya and Zonder, Jeffrey A and Shah, Mansi R and Lentzsch, Suzanne and Baz, Rachid and Maly, Joseph J and Namburi, Swathi and Pianko, Matthew J and Ye, Jing Christine and Wu, Ka Lung and Silbermann, Rebecca and Min, Chang-Ki and Vekemans, Marie-Christiane and Munder, Markus and Byun, Ja Min and Martínez-Lopez, Joaquín and Cassady, Kaniel and DeVeaux, Michelle and Chokshi, Dhruti and Boyapati, Anita and Hazra, Anasuya and Yancopoulos, George D and Sirulnik, L Andres and Rodriguez Lorenc, Karen and Kroog, Glenn S and Houvras, Yariv and Dhodapkar, Madhav V},
  title = {Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma},
  journal = {Journal of Clinical Oncology},
  year = {2024},
  volume = {42},
  number = {22},
  pages = {2702--2712},
  doi = {10.1200/jco.24.01008}
}
Kostenlos starten →